GILD

Gilead Sciences, Inc. Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Gilead Sciences, Inc. is a biopharmaceutical company focused on HIV, viral hepatitis, cancer, and inflammation. The company operates as a single operating segment managed on an entity-wide basis. As of April 30, 2025, there were approximately 1.24 billion shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $1.3 billion in Q1 2025, a significant improvement from a net loss of $4.2 billion in Q1 2024. This swing is primarily attributable to the absence of a $3.9 billion acquired in-process research and development (IPR&D) expense related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge related to Trodelvy, both of which occurred in Q1 2024.
• Revenue Stability: Total revenues remained relatively flat at $6.7 billion. Growth in HIV (up 6%) and Liver Disease (up 3%) sales offset declines in Veklury (down 45%) and Oncology (down 4%).
• Expense Reduction: Research and development expenses decreased 9% to $1.4 billion, and Selling, General, and Administrative (SG&A) expenses decreased 8% to $1.3 billion, driven by lower restructuring costs and the absence of one-time acquisition-related stock-based compensation.
• Debt Repayment: In February 2025, the company repaid $1.75 billion of senior unsecured notes due at maturity, reducing total debt.

Guidance, Outlook, and Risks

• Strategic Updates:
  • HIV: FDA accepted a New Drug Application for twice-yearly lenacapavir for HIV prevention; EMA validated the application for parallel review.
  • Oncology: Trodelvy plus Keytruda showed statistically significant improvement in progression-free survival in triple-negative breast cancer (Phase 3 ASCENT-04).
  • Inflammation: Received conditional marketing authorization in Europe for seladelpar for primary biliary cholangitis (PBC).
  • Collaborations: Entered a strategic partnership with LEO Pharma for STAT6 programs ($250 million upfront payment) and amended the Galapagos collaboration agreement ahead of a planned corporate separation.
• Capital Allocation: The company repurchased $730 million of common stock in Q1 2025 and declared a quarterly dividend of $0.79 per share. Approximately $2.0 billion remains available under the current stock repurchase program.
• Risks and Contingencies:
  • Legal Proceedings: Ongoing litigation regarding generic challenges to Biktarvy (trial scheduled for October 2025) and antitrust/consumer protection class actions. A settlement of approximately $200 million was accrued in April 2025 regarding a government investigation into promotional speaker programs.
  • Regulatory: Continued evaluation of the impact of the Inflation Reduction Act (IRA) on pricing and rebates, particularly regarding the redesigned Medicare Part D program.
  • Equity Investments: Net unrealized losses on equity securities increased to $426 million in Q1 2025 compared to $14 million in Q1 2024, impacting "Other (income) expense, net."

Investor Verification Checklist

• One-Time Charges: Verify the non-recurring nature of the Q1 2024 IPR&D charges ($6.3 billion total) to accurately assess normalized earnings power.
• Equity Valuation: Review the fair value of equity investments (Arcellx, Galapagos, Arcus) and the impact of unrealized losses on net income.
• Patent Litigation: Monitor the October 2025 trial date for Biktarvy generic challenges, which could materially impact future HIV revenue.
• Debt Maturities: Confirm the schedule of remaining senior unsecured notes and the company's ability to service debt given the recent $1.75 billion repayment.
• Regulatory Pipeline: Track the approval status of lenacapavir for HIV prevention and the commercial launch of seladelpar in Europe.